XML Template (2009) [7.9.2009–9:27am] [1–14]
{TANDF_FPP}CMO/CMO_A_370737(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
as
b.i.d.
mg
0.6)
mg
0.4)
2.4)
0.2)
C0
50 41.6 39.6
C0
11.1 13.5
10.3) 35.1 33.5 40.4 39.0
C0
97.7 94.0
8.6,
1000 149
C6 C6
5.4, C6 C6
C6 C6 C6 C6
8.9,
C6
expressed
(
C0
149
(4.1,
149
(
C0 149
13.9,
(
C0
149
C6
are
MF
(
C0
191.3 182.5 4.1 147.3 135.9 143.0
Sitagliptin
þ
3.0
43.9 46.6
7.2
112.2 103.7
C0
C0
5.7
158.0
C0
7.1
data
C0
b.i.d
baseline
from
b.i.d.
change
mg
1.2) 4.4) 0.8)
2.7)
%
50
mg
47.2 43.2 9.3
11.3
8.3)
39.1 37.1 47.3 42.8 95.8
500
5.1,
139
C6 C6
3.8,
C6 C6
5.9,
104.2
C6 11.9,
(
C0 137
C6
C6
C6 C6
(1.9,
136
(
C0 137
(
C0 139
C6
MF
(
C0
median;
195.7 189.1 1.3
43.7
45.4
5.1 115.1 110.1 0.3 151.4 143.4 2.5
for
Sitagliptin
þ
C0 C0 C0
155.0
147.0
4.6
C0
SD
C6
b.i.d.
*
median
or
b.i.d.
(SD)
mg
3.9)
42.0 39.5
4.0)
10.8 12.0
11.2) 33.4 36.7 42.8 40.2
3.7)
92.1 16.4)
5.8, deviation
population).
1000 130
C6 C6
1.1,
(
C0
130
C6 C6
(4.6,
128
C6 C6
(
C0 130
C6 C6
3.2,
130
C6
124.7
C6
(
C0 (0.5,
188.8 188.6
1.5
43.3 46.4
7.9
107.3 102.5 0.9 145.5 142.2
0.2
150.0
174.5 8.4
(CAPT
C0
standard
C6
Metformin
cholesterol.
phase mean
as
b.i.d
lipoprotein
continuation
mg
3.2) 2.7)
the
41.6 39.7
3.1)
9.0
11.0
9.4)
32.3 33.6 41.4 39.6
13.0)
expressed
4.8,
104.2 120.0
are
in
500
111
C6 C6
2.5,
(
C0
111
C6
C6
(2.3,
111
C6 C6
7.3,
(
C0 111
C6 C6
(
C0 111
C6 C6
3.3,
low-density
(
C0 data
and 186.4 186.4
42.8
45.2
5.8 105.3 102.3 2.0 143.6 141.3 1.0 54
A
0.3
C0 C0
167.0 173.0
4.9
LDL-C,
Metformin week
phase
and
both
in
q.d.
baseline
CI).
cholesterol;
mg
therapy
42.3 42.3
4.8)
9.5 9.1
4.8)
35.1 34.5
6.9)
40.3 42.5
6.8)
87.4 94.0
9.7)
(95%
100
96
C6 C6
1.2,
95
C6 C6
3.0,
94
C6 C6
4.5,
95
C6 C6
1.3,
96
C6 C6
8.9,
analysis;
lipoprotein
(
C0
(
C0
(
C0
(
C0
(
C0
active
the
change
193.0 193.5
42.0 42.1
1.8 0.9
115.1 113.5
1.2
150.5 151.1
2.7
147.5 162.5
0.4
in
Sitagliptin percent
high-density
receiving
included
data median
HDL-C,
groups
or
for
CI)
evaluable
(95%
cholesterol;
profiles
n
n
with
total
lipid
n n baseline
change
n
patients
TC,
from from from
(mg/dL),
(mg/dL),
from change baseline
of
Fasting
*
*
%
percent
54
(mg/dL),
54 54
5.
baseline baseline
(mg/dL),
54
baseline
54
from
(mg/dL),
change change change change
number
mean
metformin;
Parameter TC Baseline Week % HDL-C Baseline Week % LDL-C Baseline Week % Non-HDL-C Baseline Week % Triglycerides Baseline Week Median
¼
n LS MF,
Table
!
2009 Informa UK Ltd
www.cmrojournal.com 54-week efficacy and safety of sitagliptin/metformin Williams-Herman et al.
11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34